4.4 Review

Complexity of skeletal muscle degeneration: multi-systems pathophysiology and organ crosstalk in dystrophinopathy

Journal

PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
Volume 473, Issue 12, Pages 1813-1839

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00424-021-02623-1

Keywords

Dystrophin; Duchenne muscular dystrophy; Fibrosis; Inflammation; Muscle degeneration; Organ crosstalk

Categories

Funding

  1. Kathleen Lonsdale Institute for Human Health Research, Maynooth University

Ask authors/readers for more resources

Duchenne muscular dystrophy is a progressive muscle wasting disorder with systemic effects on various organs, requiring comprehensive biomarker signatures and novel disease markers for differential diagnosis, prognosis, and therapy monitoring. Current therapeutic approaches to combat muscular dystrophy are also summarised.
Duchenne muscular dystrophy is a highly progressive muscle wasting disorder due to primary abnormalities in one of the largest genes in the human genome, the DMD gene, which encodes various tissue-specific isoforms of the protein dystrophin. Although dystrophinopathies are classified as primary neuromuscular disorders, the body-wide abnormalities that are associated with this disorder and the occurrence of organ crosstalk suggest that a multi-systems pathophysiological view should be taken for a better overall understanding of the complex aetiology of X-linked muscular dystrophy. This article reviews the molecular and cellular effects of deficiency in dystrophin isoforms in relation to voluntary striated muscles, the cardio-respiratory system, the kidney, the liver, the gastrointestinal tract, the nervous system and the immune system. Based on the establishment of comprehensive biomarker signatures of X-linked muscular dystrophy using large-scale screening of both patient specimens and genetic animal models, this article also discusses the potential usefulness of novel disease markers for more inclusive approaches to differential diagnosis, prognosis and therapy monitoring that also take into account multi-systems aspects of dystrophinopathy. Current therapeutic approaches to combat muscular dystrophy are summarised.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available